lenvatinib

This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of

Latest news

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib)
Roche’s Tecentriq/Avastin combo improves survival in liver cancer

Merck is testing Keytruda alongside partner Eisai’s kinase inhibitor Lenvima (lenvatinib) – already-approved for first-line HCC – in the Leap-002 trial, picking up a breakthrough designation from the FDA
Merck CFO: we’re not only about Keytruda

He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer
Merck says it has plenty in the pipe beyond Keytruda

AstraZeneca-partnered Lynparza (olaparib) and Eisai-partnered Lenvima (lenvatinib) that the company is also expecting to show significant growth in the coming years.
Analysts look beyond Keytruda in Merck’s future

Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively.

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Principal Medical Writer: Varies on experience

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Content Editor - Biotechnology: Salary TBC

Account Management: Competitive Salary Offered

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....